RXC004 pre-clinical profile

RNS Number : 4849Q

Redx Pharma plc

30 November 2016

 

30 November 2016

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company" or "the Group")

Pre-clinical profile of Porcupine inhibitor RXC004 presented at EORTC-NCI-AACR 2016

Redx, the drug development company, is pleased to announce that it will present the pre-clinical profile of its Porcupine inhibitor RXC004 at the 28^th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium in Munich, Germany, on 30 November 2016.

Redx's Porcupine inhibitor RXC004 exhibits potent and selective inhibition of the Wnt pathway in in vitro and in vivo models of Wnt dependant pancreatic cancer. Preliminary results indicate that RXC004 may also enhance the efficacy of checkpoint inhibitors, such as anti-PD-1 antibodies, by reducing the proportion of regulatory T cells in the tumour microenvironment and enhancing the ratio of cytotoxic T cells to regulatory T cells in tumour infiltrates.

Pre-clinical studies are ongoing to determine the effect of RXC004 on the immune response to cancer. The Company is progressing studies to prepare the RXC004 program for first-in-human clinical trials. The aim is to commence these, initially monotherapy, trials early 2017.

Dr Neil Murray, CEO of Redx, said:

"We're delighted to present the compelling pre-clinical profile of our Porcupine inhibitor RXC004 at the EORTC-NCI-AACR Symposium.

"RXC004 has the potential to become a potent therapy for a subset of biliary, gastric and pancreatic cancer patients. It has also been shown to enhance the efficacy of checkpoint inhibitors, such as anti-PD-1 antibodies. We aim to initiate first-in-human clinical studies for RXC004 early 2017." 

The Abstract (#305) for the Poster (P131) can be found on the EORTC-NCI-AACR Symposium website: 

http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr

The Poster will be available on the Investor section of the Company's website: www.redxpharma.com/investors.html

For further information, please contact:

Redx Pharma Plc
Neil Murray, Chief Executive	T: [phone]
Karl Hård, Head of Investor Relations & Corporate Communications	T: [phone]
Cantor Fitzgerald Europe (Nomad & Broker)	T: [phone]
Phil Davies/ Michael Reynolds

About Redx Pharma Plc

Company website: Redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhoea, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

NRAAKCDDBBDBADB